Kiley Juergens Wealth Management LLC Makes New Investment in iShares Biotechnology ETF $IBB

Posted by Casey Walker on Jul 8th, 2026

Kiley Juergens Wealth Management LLC purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 2,795 shares of the financial services provider’s stock, valued at approximately $472,000.

Several other institutional investors have also recently made changes to their positions in IBB. Basepoint Wealth LLC purchased a new position in iShares Biotechnology ETF during the fourth quarter worth about $26,000. Cary Street Partners Financial LLC purchased a new stake in shares of iShares Biotechnology ETF in the 4th quarter valued at about $29,000. Darwin Wealth Management LLC purchased a new stake in shares of iShares Biotechnology ETF in the 2nd quarter valued at about $25,000. Caitlin John LLC purchased a new stake in shares of iShares Biotechnology ETF in the 4th quarter valued at about $34,000. Finally, Cornerstone Planning Group LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter valued at about $35,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ IBB opened at $198.23 on Wednesday. The business has a 50-day moving average of $174.23 and a 200-day moving average of $172.27. iShares Biotechnology ETF has a 12 month low of $128.06 and a 12 month high of $198.71.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were given a dividend of $0.0238 per share. The ex-dividend date was Monday, June 15th. This represents a $0.10 annualized dividend and a yield of 0.0%.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.